| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 15 | 2025 | 131 | 6.650 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2024 | 293 | 3.390 |
Why?
|
| Burkitt Lymphoma | 9 | 2024 | 140 | 2.210 |
Why?
|
| HIV Infections | 16 | 2023 | 2035 | 2.200 |
Why?
|
| Herpesvirus 4, Human | 9 | 2024 | 670 | 2.120 |
Why?
|
| Herpesvirus 8, Human | 3 | 2023 | 49 | 1.590 |
Why?
|
| Malawi | 18 | 2025 | 327 | 1.560 |
Why?
|
| Lymphoma | 4 | 2023 | 331 | 1.490 |
Why?
|
| Histiocytosis, Langerhans-Cell | 5 | 2025 | 241 | 1.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 1342 | 1.200 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2024 | 223 | 1.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 169 | 1.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 150 | 1.170 |
Why?
|
| Child | 43 | 2025 | 25789 | 0.950 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2025 | 15 | 0.920 |
Why?
|
| Organ Transplantation | 2 | 2024 | 180 | 0.870 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.780 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 153 | 0.770 |
Why?
|
| Lymphoma, T-Cell | 4 | 2021 | 62 | 0.710 |
Why?
|
| Adolescent | 29 | 2025 | 20562 | 0.710 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1297 | 0.660 |
Why?
|
| Interleukin-6 | 2 | 2019 | 433 | 0.640 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 293 | 0.630 |
Why?
|
| Anemia | 2 | 2023 | 350 | 0.610 |
Why?
|
| Viral Load | 4 | 2018 | 404 | 0.580 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 266 | 0.560 |
Why?
|
| Cytokines | 3 | 2021 | 1358 | 0.540 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 146 | 0.540 |
Why?
|
| Humans | 55 | 2025 | 132062 | 0.520 |
Why?
|
| Vincristine | 5 | 2020 | 196 | 0.490 |
Why?
|
| Child, Preschool | 18 | 2025 | 14751 | 0.460 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1824 | 0.420 |
Why?
|
| Lymphoma, B-Cell | 2 | 2025 | 147 | 0.390 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 1199 | 0.370 |
Why?
|
| Rituximab | 3 | 2024 | 168 | 0.370 |
Why?
|
| Methotrexate | 3 | 2025 | 350 | 0.360 |
Why?
|
| Neoplasms | 4 | 2025 | 2955 | 0.360 |
Why?
|
| Male | 29 | 2025 | 64922 | 0.360 |
Why?
|
| Hydroa Vacciniforme | 1 | 2010 | 3 | 0.340 |
Why?
|
| Female | 29 | 2025 | 70712 | 0.330 |
Why?
|
| Infant | 11 | 2025 | 13064 | 0.320 |
Why?
|
| Young Adult | 13 | 2025 | 9957 | 0.310 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 136 | 0.310 |
Why?
|
| Disease Management | 2 | 2025 | 561 | 0.300 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2025 | 221 | 0.300 |
Why?
|
| Retrospective Studies | 10 | 2025 | 17419 | 0.290 |
Why?
|
| Tanzania | 3 | 2023 | 74 | 0.280 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 519 | 0.270 |
Why?
|
| Prognosis | 6 | 2025 | 5009 | 0.260 |
Why?
|
| Bone Marrow | 3 | 2021 | 327 | 0.260 |
Why?
|
| Recurrence | 3 | 2025 | 1470 | 0.260 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1356 | 0.240 |
Why?
|
| Prospective Studies | 8 | 2025 | 6567 | 0.240 |
Why?
|
| Immunotherapy | 4 | 2022 | 745 | 0.240 |
Why?
|
| Survival Rate | 5 | 2025 | 2192 | 0.240 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 24 | 0.230 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 897 | 0.220 |
Why?
|
| Doxorubicin | 3 | 2020 | 303 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 354 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 898 | 0.200 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 194 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 177 | 0.200 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2023 | 3 | 0.200 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 428 | 0.200 |
Why?
|
| Adult | 10 | 2025 | 31568 | 0.200 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 15 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2025 | 13028 | 0.200 |
Why?
|
| HIV-1 | 2 | 2016 | 477 | 0.190 |
Why?
|
| Mucositis | 1 | 2022 | 21 | 0.190 |
Why?
|
| Morbidity | 1 | 2023 | 256 | 0.190 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 266 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 309 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 279 | 0.190 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 121 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5409 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 396 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 356 | 0.180 |
Why?
|
| Perforin | 1 | 2021 | 25 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2023 | 244 | 0.180 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 347 | 0.170 |
Why?
|
| Virus Replication | 1 | 2023 | 630 | 0.160 |
Why?
|
| Cysticercosis | 1 | 2020 | 22 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 206 | 0.160 |
Why?
|
| Bleomycin | 2 | 2020 | 113 | 0.160 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 63 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 31 | 0.160 |
Why?
|
| Anthracyclines | 2 | 2017 | 44 | 0.150 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 20 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 605 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 307 | 0.150 |
Why?
|
| Endemic Diseases | 1 | 2018 | 59 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 47 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 86 | 0.140 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 348 | 0.140 |
Why?
|
| Biopsy | 1 | 2021 | 1284 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2017 | 71 | 0.130 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 301 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 126 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 102 | 0.130 |
Why?
|
| Europe | 1 | 2017 | 372 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 187 | 0.120 |
Why?
|
| Risk | 1 | 2017 | 760 | 0.120 |
Why?
|
| Remission Induction | 1 | 2016 | 307 | 0.120 |
Why?
|
| Developing Countries | 1 | 2017 | 300 | 0.110 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3761 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 1450 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1728 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 10941 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1738 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 356 | 0.100 |
Why?
|
| Child Health Services | 1 | 2013 | 85 | 0.100 |
Why?
|
| Biomarkers | 1 | 2021 | 3406 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 69 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 236 | 0.080 |
Why?
|
| Proteomics | 1 | 2014 | 596 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3350 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8549 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2017 | 487 | 0.080 |
Why?
|
| United States | 2 | 2023 | 11658 | 0.080 |
Why?
|
| Genomics | 1 | 2017 | 1647 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1163 | 0.070 |
Why?
|
| Transcriptome | 1 | 2014 | 1125 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1952 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 814 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6229 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 231 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2508 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1960 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3681 | 0.070 |
Why?
|
| Prednisone | 2 | 2019 | 253 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6448 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4703 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 955 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2019 | 389 | 0.050 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 36 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 33 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 367 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 81 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2025 | 174 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 98 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2024 | 195 | 0.050 |
Why?
|
| Middle Aged | 5 | 2025 | 28964 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 239 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1658 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 200 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 286 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 144 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 304 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 249 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 412 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 518 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Anticestodal Agents | 1 | 2020 | 3 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 15 | 0.040 |
Why?
|
| Praziquantel | 1 | 2020 | 12 | 0.040 |
Why?
|
| Taenia solium | 1 | 2020 | 11 | 0.040 |
Why?
|
| Albendazole | 1 | 2020 | 27 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 140 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 232 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 306 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 1280 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 852 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 148 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2017 | 35 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1180 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 128 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 133 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 496 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 40 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 63 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1098 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 3736 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2024 | 2493 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 183 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 238 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 212 | 0.030 |
Why?
|
| Child Nutrition Disorders | 1 | 2013 | 42 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1454 | 0.020 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.020 |
Why?
|
| Botswana | 1 | 2013 | 76 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1558 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1491 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1353 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 97 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 668 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1797 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 762 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 233 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 491 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 34882 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 157 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3380 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1882 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 652 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 223 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2912 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 562 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1131 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 768 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1028 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 540 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 791 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1548 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1294 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7566 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 18507 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1234 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 629 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1694 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21406 | 0.010 |
Why?
|